Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODELIVERY SCIENCES INTERNATIONAL INCBDSI · Entity 128876 | Director | November 15, 2017 | November 17, 2017 |
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director | May 04, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date November 15, 2017 · Filed November 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 82,863 |
Reported balance
After 2017-11-15 transaction · row 1
1 source rowRow 1 · 2017-11-15 · Sale · Disposed 12,000 · Balance 82,863 F1: The shares of Issuer's Common Stock were sold pursuant to a pre-planned 10b5-1 plan to cover the Reporting Person's tax liability upon the vesting of RSUs in August 2017. F2: On November 15, 2017, the Reporting Person sold an aggregate of 12,000 shares of the Issuer's Common Stock at a weighted average price of $2.25 per share. The highest sale price for the Common Stock was $2.35 per share and the lowest sale price was $2.15 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Issuer's Common Stock were sold pursuant to a pre-planned 10b5-1 plan to cover the Reporting Person's tax liability upon the vesting of RSUs in August 2017.
F2: On November 15, 2017, the Reporting Person sold an aggregate of 12,000 shares of the Issuer's Common Stock at a weighted average price of $2.25 per share. The highest sale price for the Common Stock was $2.35 per share and the lowest sale price was $2.15 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Inhibitor Therapeutics, Inc.
Report date May 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,229,543 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 50,000 · Balance 1,229,543 F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed Aug 4, 2026 16:15 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-035953 · ownership.xml · nonDerivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,229,543 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. Read SEC document |
| April 01, 2025 Filed Apr 7, 2025 21:23 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-003029 · ownership.xml · nonDerivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,279,543 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| April 01, 2024 Filed May 16, 2024 17:34 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-020173 · ownership.xml · nonDerivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,129,543 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| November 15, 2017 Filed Nov 17, 2017 17:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 12,000 | $2.25 | $27,000.00 |
DisclosureSEC source: 0000899243-17-026806 · doc4.xml · nonDerivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,863 F1 · kind: The shares of Issuer's Common Stock were sold pursuant to a pre-planned 10b5-1 plan to cover the Reporting Person's tax liability upon the vesting of RSUs in August 2017. F2 · price: On November 15, 2017, the Reporting Person sold an aggregate of 12,000 shares of the Issuer's Common Stock at a weighted average price of $2.25 per share. The highest sale price for the Common Stock was $2.35 per share and the lowest sale price was $2.15 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 18:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020518 · doc4.xml · derivative · entry 4 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on July 14, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest in the first open window following the Company's 2018 Annual Meeting of Stockholders. F2 · derivative.expiration_date: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on July 14, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest in the first open window following the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 18:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020518 · doc4.xml · derivative · entry 3 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2017-08-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Restricted Stock Units ("RSUs") granted to the Reporting Person on June 30, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 18:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020518 · doc4.xml · nonDerivative · entry 2 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on July 14, 2017 under the Issuer's 2011 Equity Incentive Plan, as amended. The remaining RSUs under this grant will vest in the first open window following the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 18:02 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-020518 · doc4.xml · nonDerivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 15,000 Restricted Stock Units ("RSUs") granted to the Reporting Person on June 30, 2016 under the Issuer's 2011 Equity Incentive Plan, as amended. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 16:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantStock Options · Derivative | 15,000 | $2.64 Strike: $2.64 | $39,600.00 |
DisclosureSEC source: 0000899243-17-018424 · doc4.xml · derivative · entry 2 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-07-14 F2 · derivative.exercise_date: The stock options ("options") were issued to the Reporting Person on July 14, 2017, as compensation for service on the Issuer's board of directors. The options vest as follows: (i) 7,500 RSUs vest in the first open window following the filing of Company's quarterly 10Q for June 30, 2017 and (b) 7,500 RSUs vest in the first open window following the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 16:01 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 30,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-018424 · doc4.xml · derivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2018-08-13 F1 · derivative.exercise_date: The restricted stock units ("RSUs") were issued to the Reporting Person on July 14, 2017, as compensation for service on the Issuer's board of directors. The RSUs vest as follows: (i) 15,000 RSUs vest in the first open window following the filing of the Company's quarterly 10Q for June 30, 2017 and (b) 15,000 RSUs vest in the first open window following the Company's 2018 Annual Meeting of Stockholders. Read SEC document |
| December 01, 2016 Filed Dec 2, 2016 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 12,000 | $1.67 | $20,040.00 |
DisclosureSEC source: 0000899243-16-034863 · doc4.xml · nonDerivative · entry 1 SEARS SAMUEL P JR · CIK 0001238483 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,863 F1 · kind: The shares of Issuer's Common Stock were sold pursuant to a pre-planned 10b5-1 plan to cover the Reporting Person's tax liability upon the vesting of RSUs in August 2016. F2 · price: On December 1, 2016, the Reporting Person sold an aggregate of 12,000 shares of the Issuer's Common Stock at a weighted average price of $1.67 per share. The highest sale price for the Common Stock was $1.75 per share and the lowest sale price was $1.60 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: The Form 4 filed on August 12, 2016 inadvertently excluded 1,000 shares held by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.